



## PRESS RELEASE

### **Porsolt expands its *in vitro* drug discovery service capabilities with the acquisition of Fluofarma**

**Laval, France, 10<sup>th</sup> December 2015** – Porsolt SAS, a preclinical *in vivo* efficacy and safety CRO, has acquired Fluofarma, a Bordeaux-based company focused on the provision of cell-based assays and *in vitro* screening services. The acquisition further expands Porsolt's capabilities and services that can assist clients at earlier stages of their drug discovery programs.

Fluofarma, established in 2003, specializes in providing tailored services in cell biology and high content analysis, an approach highly solicited in association with predictive tools and cell-based models, thereby fulfilling pharmaceutical industry requirements to optimize the drug discovery pipeline. Fluofarma's expertise include *in vitro* disease models, cell-cell interaction models, assay development, and tissue analysis, all combined with the latest technologies in automated flow cytometry, high content imaging, live imaging, and high content histology. "The acquisition of Fluofarma complements Porsolt's extensive drug discovery portfolio of services and capabilities addressing multiple stages of the drug discovery process", commented Dr Guillaume Froget, President and CEO of Porsolt. "This is an exciting development for Porsolt as we continue to grow to meet the needs of our well established global client base."

Porsolt is a long established preclinical CRO with an international reputation for expertise in physio-pathological models, customized procedures, and tailored solutions for discovering treatments in multiple disease areas, including psychiatric and neurological disorders, acute and chronic pain, inflammation, cardiac and vascular diseases, metabolic and eating disorders, and dermatology, using disease models in multiple species. Porsolt also provides GLP safety evaluation of drug candidates from screening to regulatory studies before first-in-man administration, including full assessment of arrhythmogenic risk and abuse and dependence liability.

#### **About Porsolt**

Porsolt SAS, located in Le Genest-Saint-Isle, France, works with pharmaceutical and biotechnology companies, academic institutes, and not-for-profit organizations, offering specialized preclinical pharmacology services across many disease areas and physiological systems and processes. Porsolt provides services in both efficacy and GLP safety pharmacology using standardized and innovative techniques in full compliance with GLP (ICH S7). For additional information about the organization, please visit [www.porsolt.com](http://www.porsolt.com) or email us at [contact@porsolt.com](mailto:contact@porsolt.com)

#### **About Fluofarma**

Fluofarma, a Bordeaux-based company established in 2003, is a preclinical CRO that provides cell biology, *in vitro* screening platforms, and high content analysis expertise and services to companies to support drug discovery projects at early stages of development.

For additional information, please visit [www.fluofarma.com](http://www.fluofarma.com) or email us at [contact@fluofarma.com](mailto:contact@fluofarma.com)